This may be all the money Biolex needs to complete the rest of phase-2 and all of phase-3. If the FDA allows a 505b2 application, the cost (and time) of the clinical program will of course be reduced.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”